Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.06.032 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Molecular Therapy, 2025. Verfasst von Barry J Byrne und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Florida College of Medicine, Gainesville, FL 32610, USA. Electronic address: barry.byrne@ufl.edu. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Genetic Therapy, Dependovirus, Genetic Vectors. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Thrombotic microangiopathy (TMA) has been reported as an uncommon but severe adverse effect of recombinant adeno-associated virus (rAAV)-based gene therapy. Here, we describe in detail the occurrences of clinically evident TMA following infusion of the rAAV9-based therapy fordadistrogene movaparvovec (1 or 3 × 1014 vg/kg) in 22 participants with Duchenne muscular dystrophy (DMD). Three participants experienced clinical evidence of TMA. Platelet levels rapidly decreased 7-10 days post infusion, together with C3 and C4 depletion and elevated C5b-9 after ∼7 days. Peak vector blood concentration was observed for 4-7 days, and type 1 interferon cytokine levels increased within 2-7 days. Each affected participant was hospitalized and received supportive care and anti-complement therapy. Anti-AAV9 immunoglobulin M (IgM) and IgG were detected within days post infusion, and participants with TMA demonstrated a particularly rapid rise of neutralizing antibodies and total antibody to AAV9 in the first 1-2 weeks post infusion. Limited early time points from other participants were not assessed for complement activation. With appropriate monitoring of early time points following AAV exposure, TMA can be successfully managed. However, these early events should be considered related to the benefit-risk profile when using rAAV-based gene therapy for the treatment of DMD. ClinicalTrials.gov identifier: NCT03362502.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Florida College of Medicine, Gainesville, FL 32610, USA. Electronic address: barry.byrne@ufl.edu.
- University of Utah School of Medicine, Salt Lake City, UT 84132, USA.
- University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA.
- Duke University School of Medicine, Durham, NC 27705, USA.
- The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
- Pfizer Inc., New York, NY 10001, USA.
Förderung
- Pfizer
Zitieren
APA
Byrne, B. J., Butterfield, R. J., Shieh, P. B., Smith, E. C., Licht, C., Binks, M., Casinghino, S., Delnomdedieu, M., Ravindra, K. C., McDonnell, T., Ryan, K., Schulz, M., Shen, Q., Shi, H., Sirivelu, M. P., Vaidya, V. S., Whiteley, L., & Levy, D. I. (2025). Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.06.032
Vancouver
Byrne BJ, Butterfield RJ, Shieh PB, Smith EC, Licht C, Binks M, et al. Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.06.032
BibTeX
@article{Byrne2025,
author = {Byrne, Barry J and Butterfield, Russell J and Shieh, Perry B and Smith, Edward C and Licht, Christoph and Binks, Michael and Casinghino, Sandra and Delnomdedieu, Marielle and Ravindra, Kodihalli C and McDonnell, Tara and Ryan, Kelly and Schulz, Martin and Shen, Qi and Shi, Heliang and Sirivelu, Madhu P and Vaidya, Vishal S and Whiteley, Laurence and Levy, Daniel I},
title = {Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.06.032}
}
EUVIMED